Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer

Alia Daoud, Quincy S Chu, Alia Daoud, Quincy S Chu

Abstract

Discovery of the epidermal growth factor receptor gene mutation and the anaplastic lymphoma kinase chromosomal translocation in non-small cell lung cancer has prompted efforts around the world to identify many less common targetable oncogenic drivers. Such concerted efforts have been variably successful in both non-squamous and squamous cell carcinomas of the lung. Some of the targeted therapies for these oncogenic drivers have received regulatory approval for clinical use, while others have modest clinical benefit. In this mini-review, several of these targets will be reviewed.

Keywords: advanced; chromosomal rearrangement; mutations; non-small cell lung cancer; novel.

References

    1. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497–500.10.1126/science.1099314
    1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350(21):2129–39.10.1056/NEJMoa040938
    1. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2010) 11(2):121–8.10.1016/S1470-2045(09)70364-X
    1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 361(10):947–57.10.1056/NEJMoa0810699
    1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 362(25):2380–8.10.1056/NEJMoa0909530
    1. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol (2012) 30(10):1122–8.10.1200/JCO.2011.36.8456
    1. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 12(8):735–42.10.1016/S1470-2045(11)70184-X
    1. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 13(3):239–46.10.1016/S1470-2045(11)70393-X
    1. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 31(27):3327–34.10.1200/JCO.2012.44.2806
    1. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol (2014) 15(2):213–22.10.1016/S1470-2045(13)70604-1
    1. Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol (2015) 10(5):768–77.10.1097/JTO.0000000000000516
    1. Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet (2016) 387(10026):1415–26.10.1016/S0140-6736(16)00004-0
    1. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 489(7417):519–25.10.1038/nature11404
    1. Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol (2012) 13(10):e418–26.10.1016/S1470-2045(12)70291-7
    1. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 62(23):6997–7000.
    1. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res (2002) 62(23):7001–3.
    1. Litvak AM, Paik PK, Woo KM, Sima CS, Hellmann MD, Arcila ME, et al. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol (2014) 9(11):1669–74.10.1097/JTO.0000000000000344
    1. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med (2015) 373(8):726–36.10.1056/NEJMoa1502309
    1. Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol (2016) 17(5):642–50.10.1016/S1470-2045(16)00077-2
    1. Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol (2016) 17(7):984–93.10.1016/S1470-2045(16)30146-2
    1. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 364(8):772–4.10.1056/NEJMcibr1013704
    1. Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2014) 4(1):69–79.10.1158/-13-0279
    1. Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res (2012) 72(4):969–78.10.1158/0008-5472.CAN-11-1875
    1. Goetz EM, Ghandi M, Treacy DJ, Wagle N, Garraway LA. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Res (2014) 74(23):7079–89.10.1158/0008-5472.CAN-14-2073
    1. Wang J, Huang SK, Marzese DM, Hsu SC, Kawas NP, Chong KK, et al. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol (2015) 135(2):532–41.10.1038/jid.2014.418
    1. Fofaria NM, Frederick DT, Sullivan RJ, Flaherty KT, Srivastava SK. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Oncotarget (2015) 6(38):40535–56.10.18632/oncotarget.5755
    1. Vogel W, Gish GD, Alves F, Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell (1997) 1(1):13–23.10.1016/S1097-2765(00)80003-9
    1. Vogel W. Discoidin domain receptors: structural relations and functional implications. FASEB J (1999) 13:S77–82.
    1. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 1(1):78–89.10.1158/-11-0005
    1. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 28(8):1387–94.10.1200/JCO.2009.25.4029
    1. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 28(30):4609–15.10.1200/JCO.2010.30.5474
    1. Kelley MJ, Jha G, Shoemaker D, Herndon JE, II, Gu L, Barry WT, et al. Phase II study of dasatinib in previously treated patients with advanced non-small cell lung cancer. Cancer Invest (2017) 35(1):32–5.10.1080/07357907.2016.1253710
    1. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 10(2):116–29.10.1038/nrc2780
    1. Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta (2012) 1823(4):850–60.10.1016/j.bbamcr.2012.01.004
    1. Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol (2013) 31(6):731–7.10.1200/JCO.2012.43.8622
    1. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 2(62):62ra93.10.1126/scitranslmed.3001451
    1. Paik PK, Shen R, Won H, Rekhtman N, Wang L, Sima CS, et al. Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases. Cancer Discov (2015) 5(6):610–21.10.1158/-14-1129
    1. Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol (2017) 35(2):157–65.10.1200/JCO.2016.67.2048
    1. Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol (2015) 33(30):3401–8.10.1200/JCO.2014.60.7341
    1. Paik P, Shen R, Berger M, Ferry D, Soria J, Mathewson A, et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: preliminary antitumor activity and pharmacodynamic data. J Clin Oncol (2014) 32:A8035.
    1. Smyth EC, Turner NC, Peckitt C, Pearson A, Brown G, Chua S, et al. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. J Clin Oncol (2015) 33:A2508.
    1. Camidge DR, Ou S-HI, Shapiro G, Otterson GA, Villaruz LC, Villalona-Calero MA, et al. Efficacy and safety of crizotinib in patients with advanced c-MET amplified NSCLC. Proceedings of the American Society of Clinical Oncology Annual Meeting Chicago (2014). A8001.
    1. Chandrani P, Prabhash K, Prasad R, Sethunath V, Ranjan M, Iyer P, et al. Drug-sensitive FGFR3 mutations in lung adenocarcinoma. Ann Oncol (2017) 28(3):597–603.10.1093/annonc/mdw636
    1. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 431(7008):525–6.10.1038/431525b
    1. Buttitta F, Barassi F, Fresu G, Felicioni L, Chella A, Paolizzi D, et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer (2006) 119(11):2586–91.10.1002/ijc.22143
    1. Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 31(16):1997–2003.10.1200/JCO.2012.45.6095
    1. Li C, Sun Y, Fang R, Han X, Luo X, Wang R, et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol (2012) 7(1):85–9.10.1097/JTO.0b013e318234f0a2
    1. Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol (2016) 11(3):414–9.10.1016/j.jtho.2015.10.025
    1. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol (2004) 15(1):19–27.10.1093/annonc/mdh031
    1. Kris MG, Camidge DR, Giaccone G, Hida T, Li BT, O’Connell J, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol (2015) 26(7):1421–7.10.1093/annonc/mdv186
    1. De Grève J, Moran T, Graas MP, Galdermans D, Vuylsteke P, Canon JL, et al. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer (2015) 88(1):63–9.10.1016/j.lungcan.2015.01.013
    1. Smit EF, Peters S, Dziadziuszko R, Dafni U, Wolf J, Wasąg B, et al. A single-arm phase II trial of afatinib in pretreared patients with advanced NSCLC harboring a HER-2 mutation: the ETOP NICHE trial. J Clin Oncol (2017) 35:A9070.
    1. Li BT, Lee A, O’Toole S, Cooper W, Yu B, Chaft JE, et al. HER2 insertion YVMA mutant lung cancer: long natural history and response to afatinib. Lung Cancer (2015) 90(3):617–9.10.1016/j.lungcan.2015.10.025
    1. Stinchcombe T, Stahel RA, Bubendorf L, Bonomi P, Villegas AE, Kowalski D, et al. Efficacy, safety and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER-2 overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC). J Clin Oncol (2017) 35:A8509.
    1. Hainsworth JD, Bose R, Sweeney C, Meric-Bernstam I, Huriwitz H, Swanton C, et al. Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF or hedgehog alterations: interim data from MyPathway. J Clin Oncol (2017) 35:A9073.
    1. Gow CH, Liao WY, Lin YN, Shih JY. Discordant HER2 exon 20 mutation status determines a differential sensitivity to afatinib. J Thorac Oncol (2015) 10(7):e58–60.10.1097/JTO.0000000000000518
    1. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-RAS mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer (2006) 8(1):30–8.10.3816/CLC.2006.n.030
    1. Piva S, Ganzinelli M, Garassino MC, Caiola E, Farina G, Broggini M, et al. Across the universe of K-RAS mutations in non-small-cell-lung cancer. Curr Pharm Des (2014) 20(24):3933–43.10.2174/13816128113196660761
    1. Meng D, Yuan M, Li X, Chen L, Yang J, Zhao X, et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer (2013) 81(1):1–10.10.1016/j.lungcan.2013.03.019
    1. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol (2008) 9(10):962–72.10.1016/S1470-2045(08)70206-7
    1. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med (2005) 353(2):133–44.10.1056/NEJMoa050736
    1. Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2010) 28(6):918–27.10.1200/JCO.2009.25.2890
    1. Vega F, Iniesta P, Caldes T, Sanchez A, Lopez J, Dejuan C, et al. Association of K-RAS codon 12 transversions with short survival in non-small cell lung cancer. Int J Oncol (1996) 9(6):1307–11.
    1. Rosell R, Monzó M, Pifarré A, Ariza A, Sánchez JJ, Moreno I, et al. Molecular staging of non-small cell lung cancer according to K-RAS genotypes. Clin Cancer Res (1996) 2(6):1083–6.
    1. Reuter CW, Morgan MA, Bergmann L. Targeting the RAS signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood (2000) 96(5):1655–69.
    1. Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2013) 14(1):38–47.10.1016/S1470-2045(12)70489-8
    1. Jänne PA, van den Heuvel M, Barlesi F, Cobo M, Mazieres J, Crinò L, et al. Selumetinib in combination with docetaxel as second-line treatment for patients with K-RAS mutation advanced non-small cell lung cancer: results from the phase III SELECT-1 trial. European Society of Medical Oncologists Meeting. Copenhagen: (2016). Abstract LBA47_PR.
    1. Aktas H, Cai H, Cooper GM. RAS links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the CDK inhibitor p27KIP1. Mol Cell Biol (1997) 17(7):3850–7.10.1128/MCB.17.7.3850
    1. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A synthetic lethal interaction between K-RAS oncogenes and CDK4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell (2010) 18(1):63–73.10.1016/j.ccr.2010.05.025
    1. Mao CQ, Xiong MH, Liu Y, Shen S, Du XJ, Yang XZ, et al. Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery. Mol Ther (2014) 22(5):964–73.10.1038/mt.2014.18
    1. Tao Z, Le Blanc JM, Wang C, Zhan T, Zhuang H, Wang P, et al. Coadministration of trametinib and palbociclib radiosensitizes KRAS-mutant non-small cell lung cancers in vitro and in vivo. Clin Cancer Res (2016) 22(1):122–33.10.1158/1078-0432.CCR-15-0589
    1. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov (2016) 6(7):740–53.10.1158/-16-0095
    1. Drilon A, Cappuzzo F, Ou SI, Camidge DR. Targeting MET in lung cancer: will expectations finally be MET? J Thorac Oncol (2017) 12(1):15–26.10.1016/j.jtho.2016.10.014
    1. Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov (2015) 5(8):850–9.10.1158/-15-0285
    1. Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-MET overexpression. J Clin Oncol (2016) 34(7):721–30.10.1200/JCO.2015.63.4600
    1. Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res (2016) 22(12):3048–56.10.1158/1078-0432.CCR-15-2061
    1. Awad MM. Impaired c-MET receptor degradation mediated by MET exon 14 mutations in non-small-cell lung cancer. J Clin Oncol (2016) 34(8):879–81.10.1200/JCO.2015.64.2777
    1. Drilon A. MET exon 14 alterations in lung cancer: exon skipping extends half-life. Clin Cancer Res (2016) 22(12):2832–4.10.1158/1078-0432.CCR-16-0229
    1. Drilon AE, Camidge DR, Ou S-HI, Clark JW, Socinski MA, Weiss J, et al. Efficacy and safety of crizotinib in patients with advanced METex14 altered non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology Annual Meeting Chicago (2016). Abstract 108.
    1. Noonan SA, Berry L, Lu X, Gao D, Barón AE, Chesnut P, et al. Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. J Thorac Oncol (2016) 11(8):1293–304.10.1016/j.jtho.2016.04.033
    1. Schildhaus HU, Schultheis AM, Rüschoff J, Binot E, Merkelbach-Bruse S, Fassunke J. MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res (2015) 21(4):907–15.10.1158/1078-0432.CCR-14-0450
    1. Spigel DR, Edelman MJ, O’Byrne K, Paz-Ares L, Mocci S, Phan S, et al. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. J Clin Oncol (2017) 35(4):412–20.10.1200/JCO.2016.69.2160
    1. Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol (2015) 33(24):2667–74.10.1200/JCO.2014.60.7317
    1. Yoshioka H, Azuma K, Yamamoto N, Takahashi T, Nishio M, Katakami N, et al. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-MET inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Ann Oncol (2015) 26(10):2066–72.10.1093/annonc/mdv288
    1. Marchetti A, Felicioni L, Pelosi G, Del Grammastro M, Fumagalli C, Sciarrotta M, et al. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat (2008) 29(5):609–16.10.1002/humu.20707
    1. McDowall J. TRK Receptors. (2005). Available from:
    1. Passiglia F, Caparica R, Giovannetti E, Giallombardo M, Listi A, Diana P, et al. The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. Expert Opin Investig Drugs (2016) 25(4):385–92.10.1517/13543784.2016.1152261
    1. Eggert A, Grotzer MA, Ikegaki N, Zhao H, Cnaan A, Brodeur GM, et al. Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms’ tumor. J Clin Oncol (2001) 19(3):689–96.10.1200/JCO.2001.19.3.689
    1. Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, et al. Overexpression of tropomyosin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res (2005) 11(2 Pt 1):440–9.
    1. Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, et al. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs (2015) 24(11):1493–500.10.1517/13543784.2015.1096344
    1. Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther (2014) 13(5):1021–31.10.1158/1535-7163.MCT-13-0639
    1. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 68(17):6913–21.10.1158/0008-5472.CAN-07-5084
    1. Solomon B, Pearson RB. Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. J Thorac Oncol (2009) 4(7):787–91.10.1097/JTO.0b013e3181a74dba
    1. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 28(6):1075–83.10.1200/JCO.2009.25.3641
    1. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist (2011) 16(Suppl 1):12–9.10.1634/theoncologist.2011-S1-12
    1. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 27(41):5497–510.10.1038/onc.2008.245
    1. Do H, Solomon B, Mitchell PL, Fox SB, Dobrovic A. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes (2008) 1:14.10.1186/1756-0500-1-14
    1. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 18(4):1167–76.10.1158/1078-0432.CCR-11-2109
    1. Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle (2008) 7(5):665–9.10.4161/cc.7.5.5485
    1. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol (2005) 36(7):768–76.10.1016/j.humpath.2005.05.006
    1. Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer (2010) 69(3):279–83.10.1016/j.lungcan.2009.11.012
    1. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 8(5):1178–84.
    1. LoRusso PM. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol (2016).10.1200/JCO.2014.59.0018
    1. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist (2013) 18(7):865–75.10.1634/theoncologist.2013-0095
    1. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 60(4):557–63.10.1016/0092-8674(90)90659-3
    1. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol (2012) 30(35):4352–9.10.1200/JCO.2012.44.1477
    1. Sasaki H, Shimizu S, Tani Y, Maekawa M, Okuda K, Yokota K, et al. RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer. Cancer Med (2012) 1(1):68–75.10.1002/cam4.13
    1. Yokota K, Sasaki H, Okuda K, Shimizu S, Shitara M, Hikosaka Y, et al. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. Oncol Rep (2012) 28(4):1187–92.10.3892/or.2012.1908
    1. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res (2012) 22(3):436–45.10.1101/gr.133645.111
    1. Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, et al. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized phase III studies. BMC Cancer (2015) 15:171.10.1186/s12885-015-1146-8
    1. Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol (2016) 17(12):1653–60.10.1016/S1470-2045(16)30562-9
    1. Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med (2017) 5(1):42–50.10.1016/S2213-2600(16)30322-8
    1. Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer harboring RET rearrangement: a phase II clinical trial. Ann Oncol (2017) 28(2):292–7.10.1093/annonc/mdw559
    1. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. J Clin Oncol (2017) 35(13):1403–10.10.1200/JCO.2016.70.9352
    1. Zhang L, Jiang T, Zhao C, Li W, Li X, Zhao S, et al. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement. Oncotarget (2016) 7(46):75145–54.10.18632/oncotarget.12612
    1. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 30(8):863–70.10.1200/JCO.2011.35.6345
    1. Zhu Q, Zhan P, Zhang X, Lv T, Song Y. Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res (2015) 4(3):300–9.10.3978/j.issn.2218-6751.2015.05.01
    1. Cao B, Wei P, Liu Z, Bi R, Lu Y, Zhang L, et al. Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther (2016) 9:131–8.10.2147/OTT.S94997
    1. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 371(21):1963–71.10.1056/NEJMoa1406766
    1. Warth A, Muley T, Dienemann H, Goeppert B, Stenzinger A, Schnabel PA, et al. ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology (2014) 65(2):187–94.10.1111/his.12379
    1. Shaw AT, Solomon BJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2015) 372(7):683–4.10.1056/NEJMc1415359
    1. Lim S, Cho BC, Kim HR, Lee J-S, Lee KH, Lee Y-G, et al. Ceritinib in ROS1 rearranged non-small cell lung cancer: a Korean nationwide phase II study. European Society of Medical Oncologists Meeting. Copenhagen: (2016). Abstract 1205PD.
    1. Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, et al. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget (2015) 6(12):10577–85.10.18632/oncotarget.3387
    1. Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov (2017) 7(2):137–55.10.1158/-16-1123
    1. Wu X, Fu Y, Wang Y, Wan S, Zhang J. Gaining insight into crizotinib resistance mechanisms caused by L2026M and G2032R mutations in ROS1 via molecular dynamics simulations and free-energy calculations. J Mol Model (2017) 23(4):141.10.1007/s00894-017-3314-z
    1. Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, et al. Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers. Clin Cancer Res (2016) 22(24):5983–91.10.1158/1078-0432.CCR-16-0917
    1. Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clin Cancer Res (2016) 22(10):2351–8.10.1158/1078-0432.CCR-15-2013
    1. Dziadziuszko R, Le AT, Wrona A, Jassem J, Camidge DR, Varella-Garcia M, et al. An activating KIT mutation induces crizotinib resistance in ROS1-positive lung cancer. J Thorac Oncol (2016) 11(8):1273–81.10.1016/j.jtho.2016.04.001
    1. Cargnelutti M, Corso S, Pergolizzi M, Mévellec L, Aisner DL, Dziadziuszko R, et al. Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget (2015) 6(7):5182–94.10.18632/oncotarget.3311
    1. Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One (2013) 8(12):e82236.10.1371/journal.pone.0082236
    1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr, Kinzler KW. Cancer genome landscapes. Science (2013) 339(6127):1546–58.10.1126/science.1235122

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅